Kai Punasaari is developing an early-stage research proposal exploring cell-based approaches to type 1 diabetes. We seek funding for independent review, validation planning and collaboration with qualified research partners.
Type 1 diabetes involves immune-mediated loss of insulin-producing pancreatic beta cells. AI-β Cell is a research proposal exploring a cell-based response to that loss. The challenge extends beyond producing insulin: cells must respond appropriately to glucose, remain functional over time and interact safely with the immune system. The intended research examines whether durable cellular function could reduce dependence on externally administered insulin. That benefit has not been demonstrated for this project.
Patient-derived cells and beta-like function
The proposal centres on developing insulin-producing beta-like cells from a person’s own mesenchymal stem cells. Patient-derived starting material is considered as a possible route to reduce dependence on donor cells. Autologous origin does not itself resolve the autoimmune mechanisms of type 1 diabetes. Reprogramming, maturation and functional stability require separate investigation. Detecting insulin in a laboratory is insufficient: glucose responsiveness, repeatability and behaviour over time are essential parts of the proposed evaluation.
Function and immune compatibility
AI-β Cell brings metabolic function and immune compatibility into one research framework. The proposal explores genetic engineering to alter how cells interact with the immune system. Its objectives include preserving cellular function while reducing immune-mediated damage and the potential burden of prolonged immunosuppression. These are research objectives rather than established benefits. Changes intended to improve compatibility can also introduce safety questions, making traceability, controllability and unexpected cell behaviour important evaluation areas. Proprietary targets and engineering details are withheld from this public overview.
Tissue integration and durability
Producing functional cells and maintaining their function in living tissue are distinct challenges. The proposal considers access to oxygen and nutrients, interactions with surrounding tissue and long-term cell viability. Local immune responses and changes in tissue surrounding the cells could affect function over time. An early insulin measurement therefore cannot establish durable treatment success. Integration and sustained function require staged experimental assessment; specific administration procedures and implementation protocols remain confidential.
Functional, quality and safety validation
Development requires independent scientific assessment followed by laboratory and preclinical validation with qualified partners. Cell identity, purity, manufacturing consistency, glucose responsiveness and insulin secretion must be assessed together. Genomic stability, unintended cell populations, uncontrolled growth and tumour risk are central safety questions. Manufacturing changes may affect cell behaviour, so quality and function cannot be treated as a one-time check. The evaluation plans in the source proposal do not mean these studies have been completed or have produced positive results.
AI-assisted research monitoring
The proposal considers AI as a research tool for finding patterns in longitudinal metabolic and monitoring data. Time series such as continuous glucose measurements could help investigate changes in cellular function and identify observations requiring closer review. Accuracy, data quality, false alarms and performance across individuals would require validation. This concept is not presented as automated insulin dosing or an independent clinical decision system. Qualified expert oversight and appropriate data protection remain necessary.
Ethical and clinical development gates
Moving from a laboratory concept to human use is a separate development stage. Adequate preclinical evidence, appropriate manufacturing and quality systems, ethical review and relevant permissions are prerequisites to any future clinical development. The proposal treats informed consent, privacy, traceability and long-term safety follow-up as parts of that future programme. This website does not announce an authorised clinical study, patient recruitment or an available treatment. Clinical feasibility and benefit remain unverified.
Funding and scientific partnerships
Punasaari Research seeks funding and qualified scientific partners to turn the AI-β Cell proposal into measurable research work. Priorities include independent scientific review, cellular function validation, safety and quality assessment, experimental infrastructure and planning the regulatory development pathway. Funding discussions should connect each stage to research questions, verifiable outputs and criteria for progression. The public overview explains the rationale; detailed budgets, proprietary genetic targets, manufacturing parameters and administration protocols are reserved for discussions under suitable confidentiality arrangements.
Current status and disclosure boundaries
AI-β Cell is based on Kai Punasaari’s research proposal dated 23 October 2025. Its methods and anticipated effects form a development framework requiring validation. No completed experiment, peer-reviewed publication, clinical outcome or regulatory approval is claimed here. This programme is separate from GlycoCam: GlycoCam develops carbohydrate estimation software, whereas AI-β Cell concerns cell-based treatment research. Contact Kai Punasaari using the form below for scientific review or funding discussions; do not submit patient information.
The public overview is intentionally limited. Detailed methods, experimental protocols and the full manuscript are not published. Technical discussions are handled directly with prospective funding and research partners.
Clinical effectiveness has not been established. This is a research proposal, not a treatment service or patient recruitment announcement.
